Skip to main content

Table 3 Prevalence of the metabolic syndrome in specific age ranges

From: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study

  Prevalence
  NCEP 2004
n = 156
NCEP 2001
n = 149
WHO
n = 70
IDF
n = 159
EGIR
n = 47
Age < 40 years n (%) 2 (0.5) 2 (0.5) 2 (0.6) 3 (0.9) 0 (0)
Age 40 to 49 years n (%) 12 (3.1) 12 (3.1) 4 (1.1) 12 (3.4) 0 (0)
Age 50 to 59 years n (%) 32 (8.2) 29 (7.5) 15 (4.2) 32 (9.1) 12 (3.1)
Age ≥ 60 years n (%) 110 (28.3) 106 (27.2) 49 (13.6) 112 (31.9) 35 (9.0)
  1. EGIR = European Group for Insulin Resistance; IDF = International Diabetes Federation; NCEP = National Cholesterol Education Programme; WHO = World Health Organization.